![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Clears Elite, SunGen’s Adderall Generic
FDA Clears Elite, SunGen’s Adderall Generic
![ClearanceStamp_Orange.gif](https://www.fdanews.com/ext/resources/test/Device_Images6/ClearanceStamp_Orange.gif?t=1609798625&width=430)
December 18, 2018
Elite Pharmaceuticals, in collaboration with SunGen Pharma, received the FDA’s approval for generic Adderall (amphetamine, dextroamphetamine).
The approval marks the first for the collaboration between Elite and SunGen Pharma, who will jointly own the product. Elite will manufacture and package the product.
The approval marks the fifth for Elite in 2018 with three ANDAs still pending.
Upcoming Events
-
21Oct